Biosimax Lifesciences is pioneering a new model for biosimilar development, combining UK-based innovation, regulatory agility, and strategic NHS alignment to deliver high-quality biological medicines at scale. With a seasoned leadership team and strong links to academia, the MHRA, and healthcare providers, Biosimax offers a low-risk, capital-efficient pathway to market. Its platform accelerates development timelines and maximises value creation, positioning the company as a transformative force in sustainable biopharmaceutical access.